GlassScriptPhysician profile
Sunbal Javaid
NPI 1639127350
$32,378.67
in general payments reported to CMS, 2019-2025
18 companies · $50.71 in 2025
The $50.71 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $32.65 · 2021: $374 · 2022: $26K · 2023: $288 · 2024: $4,852 · 2025: $50.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $2,500 · Consulting Fee: $2,072 · Food and Beverage: $510 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $2,500.00 |
| Consulting Fee | $2,072.00 |
| Food and Beverage | $509.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $108.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $26,565.66 | 2021-2022 | |
| Abbvie INC. | $2,724.90 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,217.01 | 2024 | |
| Astellas Pharma US INC | $265.93 | 2023 | Veozah |
| Amag Pharmaceuticals, INC. | $205.80 | 2019 | |
| Allergan, INC. | $86.18 | 2019-2021 | |
| Therapeuticsmd, INC. | $67.95 | 2019 | |
| Coopersurgical, INC. | $38.57 | 2022 | |
| Endo Pharmaceuticals INC. | $35.54 | 2019-2021 | |
| Hologic Sales and Service, LLC | $34.65 | 2019 | |
| Vertical Pharmaceuticals, LLC | $32.66 | 2019-2020 | |
| Evofem Biosciences, INC. | $19.80 | 2021 | |
| Galderma Laboratories, L.P. | $19.08 | 2021 | |
| Lupin INC. | $14.28 | 2019 | |
| Millicent US INC | $14.06 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $12.82 | 2021 | |
| Duchesnay USA Incorporated | $12.54 | 2019 | |
| Currax Pharmaceuticals LLC | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunbal Javaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.